|
1
|
Watanabe M, Tachimori Y, Oyama T, Toh Y,
Matsubara H, Ueno M, Kono K, Uno T, Ishihara R, Muro K, et al:
Comprehensive registry of esophageal cancer in Japan, 2013.
Esophagus. 18:1–24. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kitagawa Y, Uno T, Oyama T, Kato K, Kato
H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al:
Esophageal cancer practice guidelines 2017 edited by the Japan
esophageal society: Part 2. Esophagus. 16:25–43. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Huddy JR, Thomas RL, Worthington TR and
Karanjia ND: Liver metastases from esophageal carcinoma: Is there a
role for surgical resection? Dis Esophagus. 28:483–487.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Miyata H, Yamasaki M, Kurokawa Y,
Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Mori M and Doki Y:
Survival factors in patients with recurrence after curative
resection of esophageal squamous cell carcinomas. Ann Surg Oncol.
18:3353–3361. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bleiberg H, Conroy T, Paillot B, Lacave
AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, et
al: Randomised phase II study of cisplatin and 5-fluorouracil
(5-FU) versus cisplatin alone in advanced squamous cell oesopahgeal
cancer. Eur J Cancer. 33:1216–1220. 1997.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Iizuka T, Kakegawa T, Ide H, Ando N,
Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M, et
al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced
squamous cell carcinoma of the esophagus: A Japanese esophageal
oncology group trial. Jpn J Clin Oncol. 22:172–176. 1992.PubMed/NCBI
|
|
7
|
Hellman S and Weichselbaum RR:
Oligometastases. J Clin Oncol. 13:8–10. 1995.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jamel S, Tukanova K and Markar S:
Detection and management of oligometastatic disease in oesophageal
cancer and identification of prognostic factors: A systematic
review. World J Gastrointest Oncol. 11:741–749. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li J, Wen Y, Xiang Z, Du H, Geng L, Yang
X, Zhang Y, Bai J, Dai T, Feng G, et al: Radical radiotherapy for
metachronous oligometastasis after initial treatment of esophageal
cancer. Radiother Oncol. 154:201–206. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ohkura Y, Shindoh J, Ueno M, Iizuka T and
Udagawa H: Clinicopathologic characteristics of oligometastases
from esophageal cancer and long-term outcomes of resection. Ann
Surg Oncol. 27:651–659. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Baba Y, Watanabe M, Kawanaka K, Iwagami S,
Ishimoto T, Iwatsuki M, Yoshida N, Yamashita Y and Baba H:
Radiofrequency ablation for pulmonary metastases from esophageal
squamous cell carcinoma. Dis Esophagus. 27:36–41. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dawood O, Mahadevan A and Goodman KA:
Stereotactic body radiation therapy for liver metastases. Eur J
Cancer. 45:2947–2959. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lehrer EJ, Singh R, Wang M, Chinchilli VM,
Trifiletti DM, Ost P, Siva S, Meng MB, Tchelebi L and Zaorsky NG:
Safety and survival rates associated with ablative stereotactic
radiotherapy for patients with oligometastatic cancer: A systematic
review and meta-analysis. JAMA Oncol. 7:92–106. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Palma DA, Olson R, Harrow S, Gaede S,
Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP,
et al: Stereotactic ablative radiotherapy for the comprehensive
treatment of oligometastatic cancers: Long-term results of the
SABR-COMET phase II randomized trial. J Clin Oncol. 38:2830–2838.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Palma DA, Salama JK, Lo SS, Senan S,
Treasure T, Govindan R and Weichselbaum R: The oligometastatic
state - separating truth from wishful thinking. Nat Rev Clin Oncol.
11:549–557. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Morinaga T, Iwatsuki M, Yamashita K,
Harada K, Kurashige J, Nagai Y, Iwagami S, Baba Y, Yoshida N and
Baba H: Oligometastatic recurrence as a prognostic factor after
curative resection of esophageal squamous cell carcinoma. Surg
Today. 51:798–806. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rusthoven KE, Kavanagh BD, Cardenes H,
Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin
W, Kane M, et al: Multi-institutional phase I/II trial of
stereotactic body radiation therapy for liver metastases. J Clin
Oncol. 27:1572–1578. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guckenberger M, Lievens Y, Bouma AB,
Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B,
Hurkmans C, Lecouvet FE, et al: Characterisation and classification
of oligometastatic disease: A European society for radiotherapy and
oncology and European organisation for research and treatment of
cancer consensus recommendation. Lancet Oncol. 21:e18–e28.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ghaly G, Harrison S, Kamel MK, Rahouma M,
Nasar A, Port JL, Stiles BM and Altorki NK: Predictors of survival
after treatment of oligometastases after esophagectomy. Ann Thorac
Surg. 105:357–362. 2018.PubMed/NCBI View Article : Google Scholar
|
